Long-term Safety Study of BMN 351 for Duchenne Muscular Dystrophy
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study continues treatment with an investigational medicine called BMN 351 for people with Duchenne muscular dystrophy (a genetic muscle-weakening condition). It checks whether the medicine remains safe and effective when used over a longer period, building on results from an earlier trial.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You completed the previous BMN 351 trial (called 351-201) and did not stop the study medication permanently
- You are currently taking oral corticosteroids (steroid pills) on a stable, consistent dose
- You do not have a known bleeding or blood-clotting disorder
- You are not taking other DMD treatments like exon-skipping therapies, gene therapy, blood thinners, or immunosuppressants
- If sexually active and able to have children, you can use and commit to contraception during the study and for 90 days after your final dose
- You can attend all study visits and follow the study schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This long-term study is for people with Duchenne muscular dystrophy who have already completed an earlier trial of the study medicine. It aims to check the safety and effectiveness of the treatment over a longer period.
This is a long-term follow-up study for people with Duchenne muscular dystrophy who already took part in a previous SAT-3247 trial. It checks how safe and effective the treatment stays over a longer time.
This trial tests an experimental drug called ENTR-601-45 for people with Duchenne muscular dystrophy that can be treated with 'exon 45 skipping.' The goal is to see if it's safe and helps improve muscle function. It's for males between 4 and 20 who can still walk and have enough arm strength.
This early-phase study tests a new gene therapy called BBM-D101 for boys with Duchenne muscular dystrophy (DMD). The goal is to see if it is safe and helps improve muscle function in young boys.
This study tests whether a new medicine called zeleciment rostudirsen can help ambulatory (walking) males with Duchenne muscular dystrophy (DMD). The medicine is given as an intravenous infusion (through a vein) every 4 weeks and works by helping the body produce a protective muscle protein.
This trial tests a new medicine called ENTR-601-44 for people with Duchenne muscular dystrophy whose genetic mutation can be treated by skipping a part of the gene called exon 44. The goal is to see if it is safe and helps with muscle function.
Hear when a new Duchenne Muscular Dystrophy (DMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.